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Abstract: Background: Adipokines play a role in pathogenesis and progression of certain cancers. Resistin is 
an adipokine with diverse findings in disease development and progression. The present study 
aimed to determine Resistin serum levels in bladder cancer cases in order to identify novel tumor 
markers.  
Methods: This research was based on a case-control study, including 45 patients with bladder can-
cer and 45 healthy controls. Resistin levels were measured by ELISA in both groups. Height and 
weight were measured and body mass index (kg/m2) was calculated.  
Results: Resistin levels were significantly different between bladder cancer and the control group 
(p<0.0001) but Resistin levels in different stages were not significantly different. Also there was no 
correlation among sex, age, body mass index and the serum Resistin levels.  
Conclusion: These results suggest that changes in serum Resistin levels play an important role in 
the diagnosis and could act as a biomarkers for bladder cancer. 
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ladder cancer (BC) is one of the most common 
malignancies in the worldwide. The American 
Cancer Society’s estimates for bladder cancer in the 
United States (US) for 2017 are: About 79,030 new cases 
and about 16,870 deaths from BC. Bladder cancer ac-
counts for about 5% of all new cancers in the US [1]. De-
spite significant advances in treatment, bladder cancer 
continues to be an extremely common disease with high 
mortality. 
The most common form of BC is transitional cell carci-
noma (TCC), constituting approximately 95 % of all 
cases. The disease has a five times higher prevalence 
among men than women, and the median age at diagno-
sis is 65 years. However, these tumors have a 30% to 
70% recurrence rate and may progress to invasive in 
10% to 30% of patients [2, 3]. Therefore, the early de-
tection of bladder cancer is essential for improved pa-
tient prognosis and long term survival.  
There are many factors that contribute to bladder car-
cinogenesis such as cigarette smoking, occupational ex-
posure to specific carcinogens such as arsenic and aro-
matic amines, schistosomal infection, chronic bladder 
problems and familial history of cancer [4]. In the past 
decades, extensive evidence suggested potential associ-
ations between obesity and many cancers such as pan-
creas, esophagus colorectal, endometrium and breast 
cancer [5-9]. Epidemiological studies have reported in-
consistent associations between body mass index (BMI) 
and bladder cancer risk. A meta-analysis published in 
2013 obesity was associated with a 10% increase in risk 
of bladder cancer [10].  
Obesity is associated with increase in adipose tissue. 
Adipose tissue is an active endocrine organ has a major 
role in the secretion of a large number of bioactive pep-
tides called Adipokines or Adipocytokines [11]. Adi-
pokines have a role in blood pressure, glucose and lipid 
metabolism, insulin resistance, inflammation, athero-
sclerosis and cancer in a paracrine or endocrine manner 
[12, 13]. The roles of some adipokines which are in-
creased with fat accumulation in carcinogenesis have 
recently drawn many researchers’ attentions. Resistin is 
an adipokine which has been shown to be highly ex-
pressed in urine some cancers [14]. It is a member of 
family of cysteine-rich proteins called “Resistin-like 
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molecules” (RELMs). Its gene, called Retn mapping to 
the p13.3 band of chromosome, encoded a 114-amino 
acid polypeptide which is secreted as a disulphide 
linked homo-dimer and circulates in two distinct assem-
bly states: an abundant high-molecular weight hexamer 
and a less abundant, but more bioactive, trimmer [15]. 
Recently, has been shown that Resistin highly expressed 
in urine sample of BC patients [16]. Since the sample 
size was too small, will need to be validated in larger 
studies and also in serum samples of BC cases in order 
to identify novel tumor markers. 
Leptin promotes proliferation and suppresses apopto-
sis in prostate cancer cell lines [15], whereas adiponec-
tin decreases proliferation of prostate cancer cells [16]. 
Although a role for adipokines such as leptin and adi-
ponectin in prostate cancer has been partially demon-
strated [17,18], the role of resistin in affecting prostate 
cancer cells has never been studied. Resistin is a re-
cently identified adipocyte-derived hormone that was 
originally proposed to link obesity with diabetes [19]. 
Serum concentrations of resistin have been reported to 
be markedly elevated in obese mice and can be de-
creased by treatment with thiazolidines [19]. Housa et 
al. [20] reported that serum resistin levels do not signif-
icantly differ between patients with BPH and prostate 
cancer, but there is a trend towards a decrease in resis-
tin serum levels in advanced cancer cases. 
The aim of this study is to evaluate the Resistin serum 
levels in BC cases compared with the control group in 




2.1. Patients:  
Patients who were admitted to the Urology ward of Sho-
hada e Tajrish hospital, Shahid Beheshti University of 
Medical Sciences, Tehran, Iran, with written consent 
were used in this study. The case population consisted 
of 45 patients, including (6 females and 37 males) with 
bladder cancer. Diagnosis of BC was confirmed by 
pathologists, also, 45 (9 females and 34 males) healthy 
people were selected as a control group from first de-
gree relatives of patients without bladder disorders 
with age, sex and BMI matched with each case group.  
This study was approved by an Institutional Review 
Board and Ethics Committee of Infertility & Reproduc-
tive Health Research Center, Shahid Beheshti University 
of Medical Sciences. 
2.2. 2.1. Anthropometric profiles 
Height was measured without shoes with Stadiometer 
(with a sensitivity of 0.5 cm), and weight with light 
clothing and without shoes was measured by scale bal-
ance (with a sensitivity of 250g) for computing body 
mass index (kg/m2). Body mass index (BMI) is a meas-
ure of weight adjusted for height that was calculated by 
as weight (kg) divided by height2 (m) according to the 
World Health Organization. Demographic information 
such as age and sex were also recorded. 
2.3. 2.2. Blood collection and hormone assays 
Blood samples were collected from both groups. For se-
rum preparation, three ml of blood from a vein of the left 
arm in a fasting position was collected and incubated for 
5 min at room temperature to clot, then centrifuged at 
3000rpm for 10 minutes. The isolated serum samples 
were stored at -80OC until assayed. 
In groups, serum Resistin levels were measured using 
ELISA according to the manufacturers’ instructions. Hu-
man Resistin hormone were determined by the sand-
wich ELISA. The kits used were prepared by the ZellBio 
GmbH, Ulm, Germany. The sensitivity of Resistin kits 
was 0.01ng/mL. The ELISA reader was from Tecan Aus-
trian Company and Sunrise Model.   
2.4. 2.3. Statistical analysis 
Kolmogorov-Smirnov test were used to check the nor-
mality of samples. Resistin was not normally distributed 
in two groups of patients and control. Mann-Whitney 
test was used to examine differences in mean variables 
for both groups. BMI and age data were normally dis-
tributed. For checking differences of mean data between 
sex, age and BMI, Independent t-test was used for both 
groups separately. All data was analyzed using statisti-
cal software (SPSS 19). A P-value <0.05 was considered 
statistically significant. 
   
3. Result 
Table 1 summarizes the demographic and anthropo-
metric characteristics of all the subjects, as well as in 
each sex group separately. There was no correlation 
among sex, age, body mass index and the serum Resistin 
levels (p>0.05). 
Resistin levels were significantly different between 
bladder cancer and the control group (p<0.0001) (Fig-
ure 1). 
Table 1: Demography and anthropometric character-
istics of participants. 
Variable 
Sex (n) Age (year) BMI (kg/m2) 
Controls Female (9) 68 ± 12.05 28.4 ± 4.78 
 Male (34) 63 ± 5.35 27.4 ± 11.06 
Patients Female (6) 66 ± 17.07 31.3 ± 17.38 
 Male (37) 68 ± 12.18 24.3 ± 3.34 
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4. Discussion 
Bladder cancer is one of the most prevalent cancers in 
the worldwide. Early detection of cancers improve sur-
vival, outcome and reduce recurrence. The development 
of molecular assays that could diagnose bladder cancer 
at an early stage, would be a significant advance. Numer-
ous molecular markers for bladder cancer are isolated 
from tissue, serum and urine that have been identified 
and investigated with various laboratory techniques. 
In this study observed that circulating Resistin levels 
were significantly increased in bladder cancer patients 
as compared to controls. These results are in agreement 
with other studies which found higher levels of Resistin 
in patients with colorectal, gastric, breast and lung can-
cer [17-19]. It has been suggested that high Resistin lev-
els are related to cancer associated chronic inflamma-
tion. 
Recent data indicate that Resistin accumulate at the site 
of inflammation and supports the inflammatory process 
by triggering cytokine production and NF-κB activation 
while simultaneously up-regulating its own expression. 
Also pro-inflammatory cytokines (IL-1, IL-6, and TNF-α) 
increase the expression of Resistin in humans periph-
eral blood mononuclear cells (PBMC) that seem to be a 
major source of Resistin [20]. 
Several studies have shown that Resistin have prolifer-
ation effects. For example, Kolosova and et al. have 
shown Resistin promotes smooth muscle cell prolifera-
tion through activation of extracellular signal-regulated 
kinase 1/2 and phosphatidylinositol 3-kinase pathways 
(36). Kolosova and et al have shown Resistin-Like Mol-
ecule α stimulates proliferation of mesenchymal stem 
cells [21]. Kim and et al have shown Resistin induces 
prostate cancer cell proliferation through PI3K/Akt sig-
naling pathways [22]. Also in previous study we showed 
that Resistin induces gastric cancer cell proliferation 
and increases Human Telomerase Reverse Transcrip-
tase (hTERT) gene expression [23, 24]. More study are 
necessary to understand the mechanism of Resistin on 
bladder cancer. 
In this article, we assess the performance of current di-
agnostic assays for bladder cancer and discuss some of 
the emerging biomarkers that could be developed to 
augment current bladder cancer detection strategies. 
According to this article results, suggest that changes in 
serum Resistin levels are not just due to obesity but be-
cause of the accumulation of inflammation. Therefore, it 
is play an important role in the diagnosis and could act 
as a biomarker for bladder cancer. 
 
5. Conclusion: 
These results suggest that changes in serum Resistin 
levels play an important role in the diagnosis and could 
act as a biomarker for bladder cancer. 
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Figure 2: Comparison of mean serum Resistin con-
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